Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC boosted its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 127.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,945 shares of the company’s stock after acquiring an additional 13,961 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Tango Therapeutics were worth $77,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $33,000. Teacher Retirement System of Texas boosted its position in Tango Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock valued at $45,000 after buying an additional 3,831 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $45,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Tango Therapeutics by 29.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company’s stock worth $65,000 after acquiring an additional 4,813 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Tango Therapeutics in the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Stock Performance

NASDAQ:TNGX opened at $1.49 on Tuesday. The company has a market capitalization of $161.08 million, a price-to-earnings ratio of -1.26 and a beta of 1.03. Tango Therapeutics, Inc. has a one year low of $1.11 and a one year high of $12.02. The stock has a 50-day simple moving average of $1.67 and a 200 day simple moving average of $3.01.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. On average, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Insider Buying and Selling at Tango Therapeutics

In other news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 24,268 shares of company stock worth $72,561 over the last 90 days. Insiders own 6.30% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Tango Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.33.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.